Jane Street’s Tvardi Therapeutics TVRD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-47,444
| Closed | -$204K | – | 13448 |
|
|
2025
Q4 | $204K | Buy |
+47,444
| New | +$425K | ﹤0.01% | 9681 |
|
|
2024
Q4 | – | Sell |
-1,486
| Closed | -$16.5K | – | 10882 |
|
|
2024
Q3 | $16.5K | Sell |
1,486
-8,972
| -86% | -$105K | ﹤0.01% | 9315 |
|
|
2024
Q2 | $97.1K | Buy |
+10,458
| New | +$249K | ﹤0.01% | 8735 |
|
|
2024
Q1 | – | Sell |
-2,594
| Closed | -$69.4K | – | 10256 |
|
|
2023
Q4 | $69.4K | Buy |
+2,594
| New | +$107K | ﹤0.01% | 8695 |
|
|
2023
Q3 | – | Sell |
-4,998
| Closed | -$509K | – | 9542 |
|
|
2023
Q2 | $509K | Buy |
4,998
+4,619
| +1,219% | +$636K | ﹤0.01% | 6298 |
|
|
2023
Q1 | $66.9K | Sell |
379
-1,285
| -77% | -$430K | ﹤0.01% | 8366 |
|
|
2022
Q4 | $643K | Buy |
1,664
+1,207
| +264% | +$458K | ﹤0.01% | 5715 |
|
|
2022
Q3 | $153K | Sell |
457
-316
| -41% | -$114K | ﹤0.01% | 8388 |
|
|
2022
Q2 | $254K | Buy |
773
+289
| +60% | +$101K | ﹤0.01% | 7854 |
|
|
2022
Q1 | $212K | Sell |
484
-235
| -33% | -$96.5K | ﹤0.01% | 8960 |
|
|
2021
Q4 | $315K | Sell |
719
-5,433
| -88% | -$2.73M | ﹤0.01% | 8080 |
|
|
2021
Q3 | $3.42M | Buy |
6,152
+5,338
| +656% | +$2.68M | ﹤0.01% | 3408 |
|
|
2021
Q2 | $418K | Sell |
814
-419
| -34% | -$266K | ﹤0.01% | 7576 |
|
|
2021
Q1 | $963K | Buy |
1,233
+566
| +85% | +$387K | ﹤0.01% | 5525 |
|
|
2020
Q4 | $364K | Buy |
667
+86
| +15% | +$45.1K | ﹤0.01% | 6146 |
|
|
2020
Q3 | $267K | Buy |
+581
| New | +$337K | ﹤0.01% | 6052 |
|
|
2019
Q2 | – | Sell |
-344
| Closed | -$243K | – | 5877 |
|
|
2019
Q1 | $243K | Buy |
+344
| New | +$206K | ﹤0.01% | 4476 |
|
|
2018
Q4 | – | Sell |
-375
| Closed | -$323K | – | 5876 |
|
|
2018
Q3 | $323K | Buy |
+375
| New | +$271K | ﹤0.01% | 4129 |
|
|
2017
Q4 | – | Sell |
-358
| Closed | -$176K | – | 5284 |
|
|
2017
Q3 | $176K | Buy |
358
+32
| +10% | +$16K | ﹤0.01% | 4166 |
|
|
2017
Q2 | $181K | Sell |
326
-649
| -67% | -$412K | ﹤0.01% | 4061 |
|
|
2017
Q1 | $645K | Buy |
+975
| New | +$521K | ﹤0.01% | 2592 |
|
|
2016
Q4 | – | Sell |
-732
| Closed | -$235K | – | 4733 |
|
|
2016
Q3 | $220K | Buy |
+732
| New | +$159K | ﹤0.01% | 3611 |
|
|
2016
Q2 | – | Sell |
-327
| Closed | -$73K | – | 4699 |
|
|
2016
Q1 | $73K | Buy |
327
+35
| +12% | +$10.5K | ﹤0.01% | 3929 |
|
|
2015
Q4 | $177K | Buy |
+292
| New | +$160K | ﹤0.01% | 3659 |
|
|
2014
Q2 | – | Sell |
-343
| Closed | -$230K | – | 3229 |
|
|
2014
Q1 | $230K | Buy |
+343
| New | +$203K | ﹤0.01% | 2242 |
|
Other funds holding TVRD
SPC
VCM
AFG
SAM
DWAM
Jane Street's TVRD Position: Q1 2026 in Review
Jane Street sold out of Tvardi Therapeutics (TVRD) in Q1 2026, closing a stake of 47,444 shares — an estimated $204K sold.
Jane Street first reported a position in TVRD in Q1 2014 and held it in 25 quarters. The position peaked at $3.42M in Q3 2021. 67 funds tracked by Wall St. Rank hold TVRD as of Q1 2026.
- Jane Street reported no remaining Tvardi Therapeutics position as of Q1 2026 after selling out during the quarter.
- Jane Street sold 47,444 Tvardi Therapeutics shares in Q1 2026, an estimated $204K.
- Jane Street first reported a position in Tvardi Therapeutics in Q1 2014 and held it in 25 quarters.
- Jane Street's Tvardi Therapeutics position peaked at $3.42M in Q3 2021.
- 67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2026.
Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.